​

Brainstorm Cell Therapeutics Ownership | Who Owns Brainstorm Cell Therapeutics?

OverviewRevenueFinancialsChartTranscripts

Brainstorm Cell Therapeutics Ownership Summary

Brainstorm Cell Therapeutics is owned by 11.21% insiders, and 88.78% retail investors. Vanguard US Total Market Shares ETF is the top mutual fund, with 1.33% of its assets in Brainstorm Cell Therapeutics shares.

BCLI Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockBrainstorm Cell Therapeutics-11.21%88.78%
SectorHealthcare Stocks 42.50%10.81%46.69%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20252-93.75%299-99.87%-0.03%--100.00%--100.00%
Jun 30, 2025336.45%235,908-72.76%31.40%11-8.33%3-
Mar 31, 202531-3.13%866,078238.80%1670.37%12-29.41%3-78.57%
Dec 31, 20244-89.19%48,928-99.55%-0.40%1-90.00%2-77.78%
Sep 30, 202437-26.00%10,822,353-10.37%154.37%10-52.38%9-

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard US Total Market Shares ETF1.06M1.33%-2.00
Vanguard Total Stock Mkt Idx Inv22.14K0.39%-28.58K
Fidelity Extended Market Index31.41K0.32%-
Vanguard Institutional Extnd Mkt Idx Tr26.73K0.27%-
Fidelity Total Market Index9.56K0.10%-
Fidelity Series Total Market Index7.98K0.08%-
BlackRock Extended Equity Market K62.75K0.08%-27.00
Northern Trust Extended Eq Market Idx5.32K0.05%-
NT Ext Equity Mkt Idx Fd - L5.32K0.05%-
Spartan Extended Market Index Pool E3.28K0.05%239.00

Recent Insider Transactions

DateNameRoleActivityValue
Oct 01, 2024Lebovits Chaim President & CEOBuy$6.29K
Sep 30, 2024Lebovits Chaim President & CEOBuy$5.02K
May 28, 2024Lebovits Chaim President & CEOBuy$7.77K
May 21, 2024Lebovits Chaim President & CEOBuy$14.47K
May 22, 2024Lebovits Chaim President & CEOBuy$16.00K

Insider Transactions Trends

DateBuySell
2025 Q1--
2024 Q41-
2024 Q311
2024 Q211-
2024 Q1--

BCLI Ownership FAQ

Who Owns Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics shareholders are primarily institutional investors at 0.00%, followed by 11.21% insiders and 88.79% retail investors. The average institutional ownership in Brainstorm Cell Therapeutics's industry, Biotech Stocks , is 45.24%, which Brainstorm Cell Therapeutics falls below.

Does Blackrock own Brainstorm Cell Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Brainstorm Cell Therapeutics.

Who is the top mutual fund holder of Brainstorm Cell Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Brainstorm Cell Therapeutics shares, with 1.33% of its total shares outstanding invested in 1.06M Brainstorm Cell Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools